Company OverviewCoronary Artery DiseaseTechnical ResourcesEmployment OpportunitiesWhat's New

Percardia CEO to Present at SG Cowen 21st Annual Health Care Conference and Announces the Appointment of Two Eminent Physicians to its Scientific Advisory Board

Merrimack, NH, March 13, 2001 /PRNewswire/ -- Percardia Inc., an early stage medical device company developing new therapeutic interventions for the treatment of coronary artery disease announced today that Ms. Nancy Briefs, the chief executive officer of the company, will present at the SG Cowen 21st Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 14th at 5:00 PM. In addition the Company is pleased to announce the addition of Martin Leon, M.D., F.A.C.C. and Peter J. Fitzgerald, M.D., F.A.C.C. to its Interventional Cardiology Scientific Advisory Board.

Dr. Martin Leon, M.D., F.A.C.C. is a Clinical Professor of Medicine at the Georgetown University Medical Center in Washington, D.C. and the Director and C.E.O. of the Cardiovascular Research Foundation and currently the Senior Attending Physician at the Lennox Hill Heart and Vascular Institute of New York. Dr. Leon is a graduate of the Yale University Medical School where he also completed his training in Internal Medicine and Cardiology and is a highly experienced clinician and thought leader in Interventional Cardiology and the treatment of Coronary Artery Disease (CAD). Dr. Leon has co-authored well over 700 publications, performed more than 5,000 procedures and participated as an investigator in numerous clinical trials.

Dr. Peter J. Fitzgerald, M.D., Ph.D., F.A.C.C. is an Associate Professor of Medicine, Associate Professor of Electrical Engineering, Co-Director, Center for Research in Cardiovascular Interventions and the Director, Core Cardiovascular Analysis Lab for the Stanford University School of Medicine. Dr. Fitzgerald earned his Ph.D. in Biomedical Engineering from Dartmouth College Thayer School of Engineering and his M.D. from Dartmouth Medical School. He completed his Residence in Medicine and Cardiology Fellowship at the University of California, San Francisco. Dr. Fitzgerald's broad clinical experience includes intravascular ultrasound, two-dimensional, color flow and Doppler echocardiography. Dr. Fitzgerald has co-authored over 200 clinical papers and abstracts on various topics in Interventional Cardiology and has participated in many important clinical trials involving the diagnosis and treatment of coronary artery disease.

Both Dr's Leon and Fitzgerald have joined the Percardia Scientific Advisory Board to assist the Company in developing its core technology, the VSTENT™ Myocardial Implant, a cardiovascular implant device that's intended to provide blood flow to a diseased coronary vessel directly from the left ventricle or chamber of the heart as well as developing the VPASS™ Percutaneous Delivery System delivery platform that will be used to place the VSTENT™ Myocardial Implant into the patients heart without performing open-heart surgery.

Nancy Briefs, CEO of Percardia commented, "We are extremely pleased that Dr's. Leon and Fitzgerald have decided to join our Scientific Advisory Board. Their collective experiences and backgrounds will add greatly to the Company's efforts in developing a percutaneous left ventricle to coronary vessel revascularization system."

The Company expects that it will add other prominent physicians and scientists as needed to safely and effectively develop its technology for the treatment of coronary artery disease. Additional information regarding the Company and its technology can be obtained at the company's website

Press Releases | Events

Company | Coronary Artery Disease | Resources | Employment | What's New

Percardia Inc.
Heron Cove Office Park
10 Al Paul Lane, Suite 202
Merrimack, NH 03054
© 2001 Percardia Inc.